Introduction
Interleukin-17C (IL-17C) is a distinct member of the IL-17-family that is induced in inflamed epithelia. IL-17C drives skin inflammation in an autocrine manner by binding to its receptor IL-17RA/IL-17RE complex, which is predominantly present on epithelial cells. Several lines of evidence point towards a role of IL-17C in driving disease activity in psoriasis 1-2 but its role in other inflammatory skin diseases remains to be elucidated. Using the MOR106 anti-IL17C antibody, we recently showed that increased skin IL-17C expression plays a role in the development of atopic dermatitis (AD) and is associated with cutaneous inflammatory responses in the calcipotriol-induced mouse model of AD [3] [4] . In addition, anti-IL-17C suppresses development of experimental psoriasis in a IL-23-driven murine skin inflammation model 5 . MOR106 is a human IgG1 monoclonal antibody derived from the MorphoSys Ylanthia® library that potently and selectively binds to human and mouse IL-17C, thereby inhibiting the binding of IL-17C to its IL-17RE receptor and thus its biological activity.
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Objective & Method
We sought to further strengthen the evidence for IL-17C as a disease relevant cytokine in AD by evaluating its role in established disease. To this end, we evaluated the therapeutic administration of the anti-IL-17C antibody MOR106 in the Flaky Tail (FT) mutant mouse strain which spontaneously develops atopy and progressive overt dermatitis due to a defective skin barrier 6-7 .
• Study outline
• All assessments were essentially done as described before [6] [7] .
• Statistical analyses were performed with a one-way analysis of variance (ANOVA) and Dunnett post hoc test. *: p<0.05; **: p<0.01; ***: p<0.001.
IL-17C drives epithelial inflammation
Conclusions
• Administration of the IL-17C neutralizing antibody MOR106 significantly attenuated the development of established AD-like inflammation in the flaky tail model of spontaneous dermatitis, with effects comparable to the treatment with a high dose of dexamethasone.
• Inhibiting IL-17C activity is a potential novel therapeutic paradigm for treating AD. MOR106 is currently evaluated in a Phase 1 study in healthy volunteers and patients with AD (NCT02739009). 
